Seegene Expands Its European Footprint with New Sales Branch in France

Seegene's New Venture in France

Seegene, a leading name in molecular diagnostics, has declared the opening of its latest sales branch in France, marking its eighth global outlet and the third in Europe. This strategic move is set to enhance its market share as it joins existing branches in Italy and Germany. With France being the second largest molecular diagnostics market in Europe, following Germany, this establishment is anticipated to address the increasing demand for various diagnostics solutions.

The French Market Landscape

According to Grand View Research Inc., the French molecular diagnostics market is estimated to be valued at around 600 million Euros, accounting for nearly 15% of the total European market. The rising demand for tests related to sexually transmitted infections, gastrointestinal diseases, and respiratory viruses has positioned France as a critical player in the diagnostics industry. Seegene aims to leverage this opportunity to boost the sale of its diagnostic products and introduce a wider array of diagnostics, including tests for cervical cancer and multiplex testing categories.

As outlined by Daniel Shin, Seegene's Executive Vice President, the ability to deliver innovative products swiftly to meet the efficiency needs of laboratories is a core competitive factor in the French market, which is divided into public and private sectors.

Enhancing Customer and Market Engagement

The new branch is set to build stronger relationships with local customers and partners by providing enhanced technical support, market development strategies, and collaborations in the healthcare sector. This will enable Seegene to gain improved insights into the French healthcare market and bolster local customer service while accelerating growth in its in vitro diagnostics segment with the help of local experts.

The branch will also serve as a strategic platform for the introduction of Seegene's innovative solutions in Europe, particularly products like the CURECA™ fully automated PCR system and STAgora™, a real-time diagnostic data analysis and forecasting platform.

Global Expansion Strategy

With the establishment of the French branch, Seegene expands its foreign sales outlets to eight, enhancing its global distribution network that now encompasses 90 distributors across 94 countries. As of the end of the first half of 2025, overseas sales accounted for approximately 93% of Seegene's total revenue, with Europe contributing around 63%. This region remains key to Seegene's development strategy, driving its ongoing global expansion efforts.

Seegene has built over 25 years of expertise in research, development, production, and commercial activities centered on real-time PCR technology for syndromic diagnostics. This experience came into play during the COVID-19 pandemic, with the company delivering over 340 million COVID-19 tests to more than 100 countries. The real-time PCR technology developed by Seegene allows for simultaneous testing of up to 14 pathogens that cause similar symptoms from a single tube sample, along with providing quantitative results.

In summary, the opening of the new branch in France represents a significant milestone for Seegene as it aims to expand its market share and further its commitment to improving health diagnostics through innovative solutions. For more information, visit Seegene.com or follow them on LinkedIn at Seegene Inc..

Note: CURECA™ and STAgora™ are in development and are not yet available for diagnostic use.